EGFR Activating Mutation
Associated Genetic Biomarkers
EGFR Activating Mutation serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain EGFR Activating Mutation as an inclusion criterion, 2 are phase 1 (2 open).
Trials with EGFR Activating Mutation in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma .
Osimertinib, sapanisertib, tegavivint, and telaglenastat are the most frequent therapies in trials with EGFR Activating Mutation as an inclusion criteria .
Significance of EGFR Activating Mutation in Diseases
Non-Small Cell Lung Carcinoma +
EGFR is altered in 22.89% of non-small cell lung carcinoma patients .
EGFR Activating Mutation is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Activating Mutation and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.